These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 35475522

  • 1. Influence of concurrent lower respiratory tract disease on point-of-care lung ultrasound in small-breed dogs with myxomatous mitral valve disease.
    Lam MC, Lin CH, Lo PY, Wu HD.
    J Vet Intern Med; 2022 May; 36(3):1075-1081. PubMed ID: 35475522
    [Abstract] [Full Text] [Related]

  • 2. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q, Heaney A, Langenfeld-McCoy N, Boler BV, Laflamme DP.
    BMC Vet Res; 2019 Nov 27; 15(1):425. PubMed ID: 31775756
    [Abstract] [Full Text] [Related]

  • 3. The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2021 Aug 27; 36():32-47. PubMed ID: 34062479
    [Abstract] [Full Text] [Related]

  • 4. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N, Nemec Svete A, Ihan A, Pohar K, Domanjko Petrič A.
    J Vet Intern Med; 2021 Sep 27; 35(5):2112-2122. PubMed ID: 34236111
    [Abstract] [Full Text] [Related]

  • 5. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Sep 27; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 6. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E, A Kobak K, Noszczyk-Nowak A, Kasztura M.
    BMC Vet Res; 2024 May 18; 20(1):210. PubMed ID: 38762716
    [Abstract] [Full Text] [Related]

  • 7. Utility of point-of-care lung ultrasound for monitoring cardiogenic pulmonary edema in dogs.
    Murphy SD, Ward JL, Viall AK, Tropf MA, Walton RL, Fowler JL, Ware WA, DeFrancesco TC.
    J Vet Intern Med; 2021 Jan 18; 35(1):68-77. PubMed ID: 33270302
    [Abstract] [Full Text] [Related]

  • 8. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S, Green D, Christley R, Dukes-McEwan J.
    J Vet Cardiol; 2019 Jun 18; 23():21-31. PubMed ID: 31174726
    [Abstract] [Full Text] [Related]

  • 9. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S, Gordon SG, Fries R, Saunders AB, Sykes KT, Vitt J, Boutet B, Häggström J, Kadotani S, Stack J, Barnett BG.
    J Vet Cardiol; 2023 Dec 18; 50():1-16. PubMed ID: 37913604
    [Abstract] [Full Text] [Related]

  • 10. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q, Wu Z, Li L, Zhou H, Chen Y, Guo S, Guo Y, Ma X, Zhang J, Feng W, Cui X, Qiu C, Xu M, Deng G.
    J Proteomics; 2023 Jun 30; 282():104924. PubMed ID: 37146676
    [Abstract] [Full Text] [Related]

  • 11. Prediction of clinically important acquired cardiac disease without an echocardiogram in large breed dogs using a combination of clinical, radiographic and electrocardiographic variables.
    Wesselowski S, Gordon SG, Meddaugh N, Saunders AB, Häggström J, Cusack K, Janacek BW, Matthews DJ.
    J Vet Cardiol; 2022 Apr 30; 40():126-141. PubMed ID: 34483077
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 13. Assessment of Lung Ultrasound B-Lines in Dogs with Different Stages of Chronic Valvular Heart Disease.
    Vezzosi T, Mannucci T, Pistoresi A, Toma F, Tognetti R, Zini E, Domenech O, Auriemma E, Citi S.
    J Vet Intern Med; 2017 May 23; 31(3):700-704. PubMed ID: 28370336
    [Abstract] [Full Text] [Related]

  • 14. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M.
    J Vet Intern Med; 2017 Mar 23; 31(2):316-325. PubMed ID: 28145607
    [Abstract] [Full Text] [Related]

  • 15. Perivascular inflammatory cells and their association with pulmonary arterial remodelling in dogs with pulmonary hypertension due to myxomatous mitral valve disease.
    Sakarin S, Rungsipipat A, Surachetpong SD.
    Vet Res Commun; 2023 Sep 23; 47(3):1505-1521. PubMed ID: 36976445
    [Abstract] [Full Text] [Related]

  • 16. Usefulness of pericardial lung ultrasonography for the diagnosis of cardiogenic pulmonary edema in dogs.
    Hori Y, Yamashita Y, Sakakibara K, Sano T, Hori A.
    Am J Vet Res; 2020 Mar 23; 81(3):227-232. PubMed ID: 32101047
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of Reticulocytosis in the Absence of Anemia in Dogs with Cardiogenic Pulmonary Edema Due to Myxomatous Mitral Valve Disease: A Retrospective Study.
    Choi SJ, Yoon WK, Ahn H, Song WJ, Choi US.
    Vet Sci; 2022 Jun 14; 9(6):. PubMed ID: 35737345
    [Abstract] [Full Text] [Related]

  • 18. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
    Hammond HH, Ames MK, Domenig O, Scansen BA, Yang NT, Wilson MD, Sunshine E, Brunk K, Masters A.
    J Vet Intern Med; 2023 Jun 14; 37(3):875-886. PubMed ID: 36951394
    [Abstract] [Full Text] [Related]

  • 19. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A, Abbott JA, Tyrrell W, Rosenthal S, Lahmers S, Menciotti G, Crosara S, Häggström J, Borgarelli M.
    J Vet Cardiol; 2021 Apr 14; 34():112-119. PubMed ID: 33706221
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease.
    Iwasa N, Kumazawa R, Nomura S, Shimizu M, Iwata M, Hara M, Kawabe M, Kobatake Y, Takashima S, Nishii N.
    J Vet Intern Med; 2023 Mar 14; 37(2):412-419. PubMed ID: 36852471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.